A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
Details
Age
Adult
Type of Study
Registry
Locations
University of Colorado Hospital
Principal Investigator
Jeffrey Bennett, MD, PhD
Study ID
Protocol Number: 23-0935
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers